Algeta Advances Amid Prostate Cancer Drug Expansion: Oslo Mover

Algeta ASA, the Norwegian drugmaker developing a treatment for prostate cancer with Germany’s Bayer AG, climbed in Oslo trading after an increase in the number of possible users of the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.